Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038532
Status:
COMPLETED
Last Update Posted:
2008-04-01
First Post:
2002-05-31
Brief Title:
AmprenavirRitonavir SaquinavirRitonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra ABT-378Ritonavir as Their First Protease Inhibitor Based HAART
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
An Open Label Phase II Study of AmprenavirRitonavir SaquinavirRitonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra ABT-378Ritonavir as Their First Protease Inhibitor Based HAART
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to study amprenavirritonavir saquinavirritonavir or efavirenz in HIV-infected patients following failure with Kaletra ABT-378ritonavir as their first protease inhibitor based HAART
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None